Partnership with Venture Capital and Grant Organizations

DEEPLAB collaborates with venture capital and grant organizations in biotech, pharma, and medtech.These partnerships support startups and fund innovation in life sciences

Venture Capital Partners

DEEPLAB maintains strategic relationships with leading venture capital firms that focus on biotech and healthcare innovations:
Chan Zuckerberg Initiative (CZI) — Invests in scalable, impact-driven companies across science, education, and health, including ventures like Citizen Health and the CZ Biohub Network.
Flagship Pioneering — Known for creating and funding groundbreaking biotech companies, including Moderna, with a focus on integrating AI into drug discovery.
ARCH Venture Partners — Invests in early-stage biotech firms, supporting the commercialization of innovative technologies.
Versant Ventures — Manages over $4 billion in assets, backing companies like CRISPR Therapeutics and Gritstone bio.
Third Rock Ventures — Focuses on building transformative biotech companies from the ground up.
OrbiMed — One of the largest investment firms dedicated to the healthcare sector, supporting companies across all stages.
Atlas Venture — Specializes in early-stage biotech investments, fostering innovation in therapeutics.
New Enterprise Associates (NEA) — Invests in a broad range of healthcare startups, providing both capital and strategic support.
Domain Associates — Focuses on healthcare investments, particularly in pharmaceuticals and medical devices.
Canaan Partners — Invests in early-stage healthcare companies, supporting their growth and development.
Astellas Venture Management — The venture arm of Astellas Pharma, investing in innovative therapeutic technologies.
Amgen Ventures — Supports early-stage biotech companies aligned with Amgen’s strategic interests.
Bristol Myers Squibb (BMS) Ventures — Invests in companies developing innovative therapies in areas of strategic interest to BMS.
Eli Lilly Ventures — Focuses on early-stage investments in biotechnology and healthcare companies.
BioGeneration Ventures — Provides early-stage funding for European life sciences companies, supporting their growth and innovation.
General Catalyst — Invests in transformative healthcare companies, aiming to redefine venture capital in the sector.
Cathay Innovation — Launched a $1 billion AI-focused venture fund to support global AI companies in digital health and other sectors.

Grant and Non-Dilutive Funding Partners

DEEPLAB also collaborates with various grant organizations to provide non-dilutive funding opportunities:
National Institutes of Health (NIH) SEED Fund — Supports early-stage biomedical startups through SBIR/STTR grants, fostering innovation in health technologies.
National Science Foundation (NSF) Biological Technologies Program — Offers grants for startups developing cutting-edge biological technologies.
Biomedical Advanced Research and Development Authority (BARDA) — Provides funding for advanced research and development of medical countermeasures.
Congressionally Directed Medical Research Programs (CDMRP) — Funds high-impact research in various medical fields, supporting innovative projects.
Advance Biotech Grant Program (Sigma-Aldrich/Merck) — Recognizes and supports emerging biotech startups with products, services, and consultation.
Alliance for Cancer Gene Therapy (ACGT) — Funds biotech companies working on cell and gene therapy projects for difficult-to-treat cancers.
Through these collaborations, DEEPLAB enhances its ability to support startups and drive innovation in the life sciences sector.